Dr Ami Sabharwal
/content/dam/asset-migration/headshots/uk-doctor-headshots/UK_Oncology_Head_shot_GA_Ami-Sabharwal.jpeg

Dr Ami Sabharwal

Dr Ami Sabharwal
Ami
Sabharwal
BSc (Hons), MBBS, MRCP, FRCR, MD, Consultant Oncologist

Languages spoken

English

Expert in

Radiotherapy techniques, brachytherapy, hormone and drug therapies and radionucleotide

Overview

Centres

Oxford
Oxford

Peters Way, Sandy Lane West, Oxford, OX4 6LB

51.7239071200697, -1.2145938932540707
/uk/our-centres/oxford
+44 (0)1865 237 700
mediahawkNumber3680 mhMobile

Specialises in

Genitourinary cancer
Condition
Condition/Cancer
Condition/Cancer/Genitourinary cancer
Prostate cancer
Condition
Condition/Cancer
Condition/Cancer/Prostate cancer

Treatments

Brachytherapy (ARSAC holder for Iodine-125)
Chemotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Chemotherapy
Hormone therapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Hormone therapy
Image-guided radiotherapy (IGRT)
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Image-guided radiotherapy
Immunotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Immunotherapy
Intensity modulated radiotherapy (IMRT)
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Intensity modulated radiotherapy
MR linac
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/MR Linac
MRIdian
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/MRIdian
Radionucleotides (ARSAC holder for Radium-223)
Radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Radiotherapy
Stereotactic ablative radiotherapy (SABR)
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Stereotactic ablative radiotherapy

Dr Sabharwal trained in London and Oxford, becoming a Consultant Oncologist in Oxford in 2009. She has a specialist interest in treating urological cancers, primarily with targeted radiotherapy (IMRT and IGRT), as well as low dose rate brachytherapy and with systemic agents (hormones, chemotherapy, biological and radionucleotide therapies).

She is an advocate for patient centred care (clear communication, patient choice and informed consent) and is research active, acting as Principle Investigator in a a number of Phase 3 clinical trials. She was Governance lead (2010-19) for Oncology (including Radiotherapy) and in addition Oncology Morbidity and Mortality chair at the Oxford University Hospitals NHS Foundation Trust. 

Career positions

Current position(s)

  • Consultant Clinical Oncologist, Oxford University Hospitals NHS Foundation Trust, Oxford

Past position(s)

  • Governance lead (2010-19) for Oncology (including Radiotherapy) and in addition Oncology Morbidity and Mortality chair at the Oxford University Hospitals NHS Foundation Trust

Expertise and interests

  • Non-surgical management of prostate and bladder cancers using advanced radiotherapy techniques, brachytherapy, hormone and drug therapies and radionucleotide

Professional memberships

  • Fellow of the Royal College of Radiologists (FRCR)
  • Member of the Royal College of Physicians (MRCP)
  • Member of the British Uro-oncology Group (BUG)
  • Member of the Medical Protection Society (MPS)
  • Member of the British Medical Association (BMA)
  • Member of the General Medical Council (GMC)